Pharmacology & biology

Triple agonist

A single molecule activating three receptors — retatrutide targets GLP-1, GIP, and glucagon receptors.

In plain terms

The logic is to combine appetite suppression, insulin sensitisation, and increased energy expenditure in one molecule. Retatrutide remains investigational; the trial results are striking, and it is not an approved drug.

Compounds where this comes up

Peptide

Retatrutide

Guides that use this term

Semaglutide vs tirzepatide: what the head-to-head trial found

SURMOUNT-5 compared them directly over 72 weeks: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide. What that number does and does not settle.

Educational reference only. Pepperz does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing recommendations.